ALLMedicine™ Acromegaly Center

Sep 18th, 2020 - Acromegaly registries constitute a valuable source of therapeutic outcome information in real-life. To analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Data was extracted from the MAR informatic platform. Sur...

Sep 17th, 2020 - Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered life-long. To date, almost 30% of patients trea...

Sep 14th, 2020 - A thorough follow-up study in which the same clinic presents the change in the surgical outcomes of acromegaly over the years, is still lacking in the endoscopic era. In this study, we intended to evaluate the clinical characteristics, radiologica...

Sep 13th, 2020 - ERRATUM FOR "Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial".|2020||

Sep 11th, 2020 - The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly manage...

Feb 25th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Dec 31st, 2015 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Oct 30th, 2014 - The aim was to formulate clinical practice guidelines for acromegaly. The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), five experts in the field, and a methodologist. The authors received no...

Feb 25th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

Aug 23rd, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

Sep 18th, 2020 - Acromegaly registries constitute a valuable source of therapeutic outcome information in real-life. To analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Data was extracted from the MAR informatic platform. Sur...

Sep 17th, 2020 - Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered life-long. To date, almost 30% of patients trea...

Sep 14th, 2020 - A thorough follow-up study in which the same clinic presents the change in the surgical outcomes of acromegaly over the years, is still lacking in the endoscopic era. In this study, we intended to evaluate the clinical characteristics, radiologica...

Sep 13th, 2020 - ERRATUM FOR "Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial".|2020||

Sep 11th, 2020 - The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly manage...

May 20th, 2018 - BOSTON – Men with acromegaly present at a younger age, have higher IGF-1 levels, and achieve lower biochemical control rates than women with the disorder, according to study results presented at the annual meeting of the American Association of Cl.

Oct 26th, 2017 - NEW YORK (Reuters Health) - An intramuscular long-acting formulation of the somatostatin analog pasireotide given monthly normalized cortisol levels in about 40% of patients with Cushing's disease and provided “sustained” clinical benefit in a pha...

Jan 26th, 2015 - SHOULD AN ASYMPTOMATIC PATIENT BE EVALUATED FURTHER? Endocrine Society guidelines2 recommend that all patients with pituitary incidentaloma, with or without symptoms, should undergo a complete history and physical examination and laboratory evalua.

Dec 18th, 2014 - A long-acting formulation of the somatostatin analogue pasireotide has been approved for treatment of acromegaly in patients “who have had an inadequate response to surgery and/or for whom surgery is not an option,” the manufacturer, Novartis, has.

Dec 16th, 2014 - ZURICH (Reuters) - U.S. health regulators have approved Novartis’ drug Signifor LAR as a treatment for a rare and life-threatening hormonal disorder, the Swiss drugmaker said on Tuesday. The Basel-based firm said the U.S. Food and Drug Administrat...